In patients with acute demyelinating neuropathies such as Guillain‑Barré syndrome or chronic inflammatory demyelinating polyneuropathy who are candidates for plasma exchange (PLEX), what is the role of intravenous immunoglobulin (IVIG) as an alternative, adjunct, or sequential therapy, including its indications, dosing regimen, and timing?

Role of IVIG in Acute Demyelinating Neuropathies with Plasmapheresis

IVIG and plasmapheresis are equally effective as monotherapies for Guillain-Barré syndrome and should NOT be combined, as combination therapy offers no additional benefit over either treatment alone. 1, 2

First-Line Treatment Selection

IVIG is the preferred first-line therapy over plasmapheresis for the following practical reasons 1, 2:

• Easier to administer without requiring central line placement
• More widely available in most clinical settings
• Higher treatment completion rates (fewer discontinuations)
• Lower complication rates compared to plasmapheresis

Standard IVIG Dosing Regimen

• 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg) 1, 2
• Treatment should be initiated within 2 weeks of symptom onset for maximum effectiveness 1, 3

When to Use Plasmapheresis Instead of IVIG

Consider plasmapheresis as first-line therapy in these specific clinical scenarios 1:

• Severe hyponatremia (IVIG can worsen fluid overload)
• High thromboembolic risk (cancer, smoking, hypertension, diabetes, hyperlipidemia, hypercoagulable states)
• Associated brain or spinal demyelination
• Bleeding disorders (where IVIG is preferred)

Plasmapheresis protocol: 5 sessions at 200-250 ml plasma/kg body weight 1

Sequential vs. Combination Therapy

Do NOT use plasmapheresis followed by IVIG or vice versa 1, 2:

• Combination therapy is no more effective than either treatment alone
• Plasmapheresis immediately after IVIG will remove the administered immunoglobulin, negating its benefit 1
• This represents unnecessary cost and increased complication risk

Exception: Treatment Failure or Progression

Add the alternative therapy only if:

• No improvement after completing the initial 5-day IVIG course 1
• Progressive worsening despite initial treatment 1
• Symptoms worsen after 3 days of treatment 1

For severe or refractory cases (Grade 3-4), consider adding pulse methylprednisolone (1 g IV daily for 3-5 days) plus IVIG or plasmapheresis 1

Special Population: Immune Checkpoint Inhibitor-Related GBS

This is the ONE exception where corticosteroids have a role 1, 3:

For ICPi-related GBS (Grade 3-4):

1. Permanently discontinue the immune checkpoint inhibitor immediately 1, 3
2. Start methylprednisolone 2-4 mg/kg/day OR pulse dosing 1 g/day for 5 days 1, 3
3. Add IVIG (0.4 g/kg/day for 5 days) OR plasmapheresis concurrently with steroids 1, 3
4. Taper steroids over 4-6 weeks after acute management 1, 3

Critical distinction: For idiopathic GBS, corticosteroids as monotherapy are ineffective and potentially harmful 1, 2, 3

Treatment-Related Fluctuations

Approximately 10% of patients experience secondary deterioration within the first 8 weeks after starting IVIG 4:

• This represents treatment-related fluctuation (TRF), not treatment failure
• Repeat IVIG treatment is indicated for TRF 4
• Do NOT interpret early lack of improvement as failure—40% show no improvement in the first 4 weeks 3

Common Pitfalls to Avoid

Do not use corticosteroids as monotherapy for idiopathic GBS—randomized trials show no benefit and oral corticosteroids may worsen outcomes 1, 2, 3

Do not delay treatment waiting for electrodiagnostic confirmation—clinical diagnosis is sufficient to initiate therapy 1

Do not combine IVIG and plasmapheresis upfront—this wastes resources without improving outcomes 1, 2

Do not use intramuscular corticosteroids—potentially serious side effects 2

Monitoring and Supportive Care

Admit to monitored unit with rapid ICU transfer capability for patients with 1, 3:

• Inability to walk unassisted
• Any dysphagia, facial weakness, or respiratory muscle weakness
• Rapidly progressive symptoms
• Vital capacity <15-20 ml/kg or <1 liter

Monitor respiratory function frequently using pulmonary function testing (negative inspiratory force/vital capacity) 1

Avoid medications that worsen neuromuscular function: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides 2

Expected Outcomes

80% regain walking ability at 6 months despite treatment 3

Mortality remains 3-10%, primarily from cardiovascular and respiratory complications 3

25% require mechanical ventilation during the disease course 1